companydata.dkNOVARTIS HEALTHCARE A/S: Financial statements 2023
CVR: 20575786
NOVARTIS HEALTHCARE A/S (CVR 20575786) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 914,827,000 and a net result of DKK 251,036,000 compared with DKK 56,162,000 the year before. That is an increase of 54.3% compared with the year before. The profit margin was 27.4%. Equity amounted to DKK 540,957,000. The solvency ratio was 83.1%. The company had 121 employees in the financial year.
- Revenue
- 914,827,000 kr.
- Gross Profit
- 160,247,000 kr.
- Profit/Loss
- 251,036,000 kr.
- Equity
- 540,957,000 kr.
- Total Assets
- 651,310,000 kr.
- Employees
- 121
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 914.8 mio. | 160.2 mio. | 251 mio. | 541 mio. | 121 |
| 2022 | 592.7 mio. | 193.4 mio. | 56.2 mio. | 289.9 mio. | 126 |
| 2021 | 701.9 mio. | 170.5 mio. | 84.9 mio. | 233.8 mio. | 125 |
| 2020 | 1 mia. | 196.8 mio. | 127.7 mio. | 148.9 mio. | 131 |
| 2019 | 966.6 mio. | 170.6 mio. | -98.6 mio. | 21.2 mio. | 126 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of May 31, 2023, Uffe Mark Hansen has joined the board of directors of NOVARTIS HEALTHCARE A/S.
As of May 31, 2023, Carsten Gleerup has left the board of directors of NOVARTIS HEALTHCARE A/S.
As of May 30, 2023, Uffe Mark Hansen has left the board of directors of NOVARTIS HEALTHCARE A/S.
NOVARTIS HEALTHCARE A/S has published its annual report for 2022. Revenue came to DKK 592,697,000, and the net result was DKK 56,162,000.
As of January 6, 2023, KPMG P/S has been appointed auditor of NOVARTIS HEALTHCARE A/S.
About NOVARTIS HEALTHCARE A/S
NOVARTIS HEALTHCARE A/S is a Danish company of the type Aktieselskab based in København S, founded in 1997. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Peter Drøidal. The company is owned by Novartis Pharma AG. The company has 125 employees.